Arcutis-sponsored research reveals unique genomic profile and distinct skin barrier disruption in seborrheic dermatitis.

New research, sponsored by Arcutis Biotherapeutics, reveals the genomic profile of seborrheic dermatitis, a unique inflammatory skin disease with its own molecular signature. The study, presented at the American Academy of Dermatology annual meeting, suggests seborrheic dermatitis skin barrier disruption is distinct with its own disease-specific pattern. This discovery may improve understanding and treatment of the condition.

March 09, 2024
5 Articles

Further Reading